

14 **Abstract**

15 Bacterial conjugation is the main mechanism for the transfer of multiple antibiotic resistance
16 genes among pathogenic microorganisms. This process could be controlled by compounds
17 that inhibit bacterial conjugation. In this study, the effect of allyl isothiocyanate, L-
18 sulforaphane, benzyl isothiocyanate, phenylethyl isothiocyanate and 4-methoxyphenyl
19 isothiocyanate on the conjugation of broad host range plasmids, which harbor various
20 resistance genes in *Escherichia coli* were investigated; pKM101 (IncN), TP114 (IncI₂),
21 pUB307 (IncP) and the low copy number IncW plasmid R7K. Benzyl isothiocyanate (32
22 mg/L) significantly reduced the conjugal transfer of pKM101, TP114 and pUB307 to
23 0.3±0.6%, 10.7±3.3% and 6.5±1.0%, respectively. L-sulforaphane (16 mg/L, transfer
24 frequency 21.5±5.1%) and 4-methoxyphenyl isothiocyanate (100 mg/L, transfer frequency
25 5.2±2.8%) were the only compounds that showed anti-conjugal specificity by actively
26 reducing the transfer of R7K and pUB307, respectively.

27

28 **Keywords:** Isothiocyanates, bacterial conjugation, conjugative plasmids, effector proteins,
29 horizontal gene transfer, plasmid incompatibility groups

30

31

32 **1. Introduction**

33 Bacterial conjugation is an adaptive mechanism that allows bacteria to transfer genetic
34 materials, effector proteins and/or toxins from one cell to the other through a conjugative
35 bridge [1, 2]. The genetic materials that are transferred via conjugation usually confer
36 selective advantages to the recipient organism, such as survival, resistance, pathogenicity,
37 infection activities and/or the ability to respond to environmental changes. Conjugation
38 greatly increases bacterial genome plasticity, and has immense clinical relevance as a major
39 route for the spread of multiple antibiotic resistance genes among the microbial community
40 and virulence genes from pathogen to host [2]. It is therefore imperative to find ways to
41 combat conjugation, as a means to decrease the ongoing rise of antibiotic-resistant infections.

42

43 Inhibition of bacterial conjugation has not received much research attention because the focus
44 has been on the identification of new classes of antibacterial agents that target processes
45 essential for bacterial growth such as cell wall biosynthesis, the cell membrane, protein
46 synthesis, nucleic acid synthesis and metabolite activity. This traditional approach has
47 produced many therapeutically useful agents so far, but the challenge is that an antibiotic also
48 introduces selective pressure promoting resistant bacteria, and therefore this has led to the
49 current antibiotic resistance crisis. An additional approach of reducing the increasing rate of
50 bacterial antibiotic resistance dissemination and re-sensitizing bacteria to existing antibiotics,
51 would be to target non-essential processes such as conjugation, which are less likely to evoke
52 bacterial resistance. This approach could also have a prophylactic use in cosmeceuticals to
53 reduce plasmid transfer. In addition to bacterial conjugation, other non-essential processes
54 such as plasmid replication [3-5] and plasmid-encoded toxin-antitoxin systems [6, 7] have
55 been exploited with promising potential in antibacterial therapy.

56 The few efforts directed towards identifying anti-conjugants include small-molecule
57 inhibitors of *Helicobacter pylori* *cag* VirB11-type ATPase Cag α [8]. The *cag* genes encode
58 for the assembly of the conjugative bridge and injection of the CagA toxin into host cells [8,
59 9]. In addition, there have been other reports of promising anti-conjugants such as
60 dehydrocrepenynic acid [1], linoleic acid [1], 2-hexadecanoic acid [10], 2-octadecanoic acid
61 [10], and tanzawaic acids A and B [11]. However, these compounds have stability, toxicity or
62 scarcity issues that need to be addressed. Therefore there is the pressing need to identify safer
63 anti-conjugants to help in the fight against plasmid-mediated transfer and spread of antibiotic
64 resistance and virulence.

65
66 In this study, four naturally occurring isothiocyanates (allyl isothiocyanate (**1**), L-
67 sulforaphane (**2**), benzyl isothiocyanate (**3**), phenylethyl isothiocyanate (**4**)) and a synthetic
68 isothiocyanate (4-methoxyphenyl isothiocyanate, **5**) were investigated for their anti-conjugant
69 activity against *E. coli* strains bearing conjugative plasmids with specific antibiotic resistance
70 genes. Isothiocyanates are usually naturally occurring hydrolytic products of glucosinolates,
71 which are commonly found in the *Brassica* vegetables. They are produced when damaged
72 plant tissue releases the glycoprotein enzyme myrosinase, which hydrolyses the β -glucosyl
73 moiety of a glucosinolate. This leaves the unstable aglycone, thiohydroxamate-*O*-sulfonate,
74 which rearranges to form an isothiocyanate or other breakdown products [12, 13]. Other
75 isothiocyanates such as 4-methoxyphenyl isothiocyanate and methyl isothiocyanate are
76 synthetically produced and not naturally occurring.

77
78 In addition to the anti-conjugant testing, plasmid curing activity and bacterial growth
79 inhibition were also evaluated to help discriminate between true anti-conjugants and
80 substances that reduce conjugation due to elimination of plasmids or function by perturbation

81 of bacterial growth or physiology. Isothiocyanates possessing the highest anti-conjugant
82 activities were further investigated for cytotoxicity against human dermal fibroblast adult
83 cells (HDFa; C-013-5C).

84

85

86 **2. Materials and methods**

87 *2.1. Bacterial strains and plasmids*

88 *E. coli* NCTC 10418 (a susceptible Gram-negative strain), *S. aureus* ATCC 25923 (a
89 susceptible Gram-positive strain), *S. aureus* SA-1199B (a fluoroquinolone-resistant strain,
90 which over-expresses the multidrug-resistant NorA pump) and *S. aureus* XU212 (a
91 tetracycline-resistant strain, which over-expresses the multidrug-resistant TetK pump) were
92 used for the broth dilution assay. Plasmid-containing *E. coli* strains WP2, K12 J53-2 and K12
93 JD173 were used as donor strains in the plate conjugation and plasmid elimination assays. *E.*
94 *coli* ER1793 (streptomycin-resistant) and *E. coli* JM109 (nalidixic-resistant) were used as the
95 recipients. Conjugative plasmids used were pKM101 (WP2; incompatibility group N (IncN);
96 ampicillin-resistant), TP114 (K12 J53-2; IncI₂; kanamycin-resistant), and R7K (K12 J53-2;
97 IncW; ampicillin-, streptomycin- and spectinomycin-resistant), which were purchased from
98 Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and conjugative
99 plasmid pUB307 (K12 JD173; IncP; ampicillin-, kanamycin- and tetracycline-resistant) was
100 provided by Prof. Keith Derbyshire, Wadsworth Center, New York Department of Health.

101

102 *2.2. Broth micro-dilution assay*

103 The antibacterial activity was determined with the broth micro-dilution method as described
104 previously [14], which is a modified version of the procedure described in the British
105 Society for Antimicrobial Chemotherapy (BSAC) guide to sensitivity testing. Bacteria were
106 cultured on nutrient agar slants and incubated at 37°C for 18 hours. A bacterial suspension
107 equivalent to a 0.5 McFarland standard was made from the overnight culture. This was added
108 to Muller-Hinton broth and the test isothiocyanate, which had been serially diluted across a
109 96-well microtitre plate, to achieve a final inoculum of 0.5×10^5 CFU/mL. Minimum

110 inhibitory concentrations (MICs) were determined after 18 hours of incubation at 37°C. This
111 was done by visual inspection after the addition of a 1 mg/mL methanolic solution of 3-[4,5-
112 dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and incubation at 37°C for 20
113 minutes. This experiment was performed in duplicate in two independent experiments.

114

115 2.3. *Liquid conjugation assay*

116 The donor cells with plasmids pKM101, TP114 and pUB307 were paired with the recipient
117 ER1793. Plasmid R7K donor cells were paired with the recipient JM109. Research has shown
118 that plasmid carriage by host bacteria is associated with some fitness cost (burden) [15, 16].
119 This fitness effect of plasmids plays a vital role in their ability to associate with a new
120 bacterial host. As a consequence of this we selected different *E. coli* host, which are known to
121 successfully conjugate [17, 18] and to maintain the study plasmids. The liquid conjugation
122 assay was performed as previously described [19] with slight modifications. Equal volumes
123 (20 µL) of donor and recipient, for which the colony forming units per mL (CFU/mL) had
124 been predetermined (Supplementary Table 1), were introduced into 160 µL of Luria-Bertani
125 broth and the test sample or control. This was incubated at 37°C for 18 hours after which the
126 number of transconjugants and donor cell were determined using antibiotic-containing
127 MacConkey agar plates. A positive control linoleic acid [1] and negative control (donor,
128 recipient and media; without drug or test sample) were included in the experiment. The
129 isothiocyanates were evaluated for anti-conjugant activity at sub-inhibitory concentration
130 (one-quarter of the MIC). Antibiotics were added at the following concentrations for positive
131 identification of donors, recipients and transconjugants (mg/L): amoxicillin (30),
132 streptomycin sulphate (20), nalidixic acid (30), kanamycin sulphate (30). Conjugation
133 frequencies were calculated as the ratio of total number of transconjugants (cfu/mL) to the
134 total number of donor (cfu/mL) and expressed as a percentage relative to the negative control.

135 This experiment was performed as duplicate in three independent experiments and anti-
136 conjugation activity is reported as the mean \pm standard deviation.

137

138 2.4. Plasmid elimination assay

139 This assay was performed as described previously [20] with minor modifications. The *E. coli*
140 donor strains were sub-cultured on appropriate antibiotic-containing MacConkey agar plates
141 to ensure plasmid presence. After incubation of the plates at 37°C for 18 hours, single
142 colonies (2-3) were selected and inoculated into LB. This was incubated for 18 h at 37°C and
143 the colony forming units were determined prior to the assay. Twenty microliters of the
144 overnight culture was then added to a mixture of 180 μ L LB and test sample in a 96 well
145 microtitre plate. This was incubated overnight (18 h) at 37°C and subsequently serially
146 diluted, 20 μ L was then plated on antibiotic containing MacConkey agar and incubated for 18
147 h at 37°C. The isothiocyanates were evaluated for plasmid elimination activity at
148 concentrations used in the liquid conjugation assay. Both positive control (promethazine) [21-
149 23] and negative control (mixture without isothiocyanate or control drug) were included in
150 this experiment. Plasmid elimination was calculated using:

$$151 \text{ Plasmid elimination} = \frac{\text{CFU/mL of control} - \text{CFU/mL of test sample}}{\text{CFU/mL of control}} \times 100$$

152 Antibiotics and concentrations used in MacConkey agar for positive identification of *E. coli*
153 cells harbouring plasmids (mg/L) were: amoxicillin (30), kanamycin sulphate (20 and 30) and
154 nalidixic acid (30). This experiment was performed in duplicate, with three independent
155 experiments.

156

157 2.5. Cytotoxicity assay

158 The isothiocyanates that showed anti-conjugant activity were further assessed for their effect
159 on eukaryotic cell growth. The sulforhodamine B (SRB) colorimetric assay as described

160 previously [24] was used, with modifications. Human dermal fibroblast, adult cells (HDFa; C-
161 013-5C) were grown in a 75 cm² culture flask at 37°C in humidified atmosphere of 5%
162 carbon dioxide using Dulbecco's Modified Eagle's Medium, which was supplemented with
163 10% fetal bovine serum (FBS), 1% non-essential amino acids, 0.1% gentamicin and
164 amphotericin B. The grown cells were seeded in a 96 well microtitre plated and test samples
165 and media were added. This was then incubated at 37°C in 5% CO₂ for 72 h. Afterwards 50
166 μL of cold 40% ^W/_V trichloroacetic acid (TCA) solution was added, the plate was placed in
167 the fridge for an hour at 4°C and washed four times with distilled water. The cells were then
168 stained with 0.4% ^W/_V SRB solution and left at room temperature for an hour. Afterwards, the
169 plate was rinsed four times with 1% acetic acid and left overnight (24 h) to dry. Thereafter,
170 100 μL of 10 mM Tris buffer solution was dispensed into the wells and agitated in an orbital
171 shaker for 5 min, to allow solubilisation of SRB-protein complex. The optical density (OD)
172 was then measured at 510 nm using a microtitre plate reader (Tecan Infinite® M200). The
173 percentage of viable cell was calculated using:

174

$$\text{Percentage of viable cell} = \frac{\text{OD of test sample} - \text{OD of blank}}{\text{OD of negative control} - \text{OD of blank}} \times 100$$

176

177 This experiment was performed as triplicate in three independent experiments and
178 cytotoxicity has been reported as mean ± standard deviation.

179

180 2.6. Statistical analyses

181 The statistical analyses were carried out using Excel Data Analysis and GraphPad Prism 7.

182 Welch's t-test was used to evaluate the difference between the control conjugal transfer

183 frequency and the test compounds. Results with $p < 0.05$ were considered statistically

184 significant.

185

186 **3. Results**

187 *3.1. The effect of isothiocyanates on the growth of bacteria*

188 To test whether the selected isothiocyanates had growth inhibitory activity against bacterial
189 species and to inform of a suitable concentration for their evaluation in an anti-conjugation
190 assay, the isothiocyanates were tested against susceptible Gram-negative (*E. coli* NCTC
191 10418) and Gram-positive (*S. aureus* ATCC 25923) standard isolates, and antibiotic effluxing
192 *Staphylococcus aureus* strains (SA-1199B and XU212). Table 1 shows the MIC values for the
193 tested isothiocyanates; their inhibitory activity varied from 16 to 512 mg/L against the
194 evaluated bacteria. Our general observation was that unsurprisingly the isothiocyanates were
195 marginally more active against the Gram-positive than the Gram-negative strains.

196

197 *3.2. The effect of isothiocyanates on conjugal transfer of plasmids*

198 To investigate whether the selected isothiocyanates have anti-conjugant activity, a range of
199 plasmids belonging to different incompatibility groups (IncN plasmid pKM101, IncI₂ plasmid
200 TP114, IncP plasmid pUB307 and IncW plasmid R7K) were employed to test the specificity
201 of conjugation inhibition in *E. coli*. With information (Table 1) about their minimum
202 inhibitory concentration against *E. coli* NCTC 10418 (a susceptible standard strain), the
203 isothiocyanates were tested at a sub-inhibitory concentration, one-quarter of their MICs.
204 Figure 1 shows the effect of the isothiocyanates on the conjugal transfer of the test plasmids.
205 The test isothiocyanates exhibited inhibitory activities ranging from complete reduction in
206 conjugation frequency (0%, considered active), inhibition of conjugation frequency to less
207 than 10% were also considered as active; 10 to 50% were considered moderately active and
208 greater than 50% were considered as inactive.

209

210 *3.3. Elimination of plasmids from E. coli*

211 To determine whether the observed anti-conjugant activity was not due to the elimination of
212 conjugative plasmids, the donor cells were grown in the presence of the test isothiocyanates,
213 and the plasmid elimination assay was performed. Figure 2 shows the effect of the
214 isothiocyanates on conjugative plasmids. The isothiocyanates exhibited varied plasmid curing
215 activity. Plasmids TP114 and R7K of the incompatibility groups I₂ and P, respectively, were
216 the most eliminated in the donor cells with elimination percentages ranging from 3.0±0.1 to
217 77.8±8.0. Most of the tested isothiocyanates did not have any plasmid curing effects on
218 pKM101 (IncN), with the exception of allyl isothiocyanate (**1**), which showed a curing effect
219 of 19.4±6.6 %. For pUB307 (IncP), a plasmid curing effect was observed for L-sulforaphane
220 (**2**, 56.7±3.2 %) and phenylethyl isothiocyanate (**4**, 64.8±15.4 %).

221

222 *3.4. The effect of increasing concentration of benzyl isothiocyanate (3) on conjugal transfer*
223 *of the plasmids pKM101 (IncN), TP114 (IncI₂) and pUB307 (IncP)*

224 With benzyl isothiocyanate (**3**) having shown broad range anti-conjugant (conjugal reduction
225 to 0.3±0.6 - 10.7±3.3%, Figure 1) and the least donor plasmid elimination activity (0 -
226 26.5±5.9%, Figure 2) of all tested compounds, it was further assessed to observe its effect on
227 conjugal transfer with increasing concentration. Generally, there was a gradual increase in
228 anti-conjugal activity against pKM101 and TP114 with increase in concentration from 0.125
229 to 64 mg/L (Figure 3). This was not the same for plasmid pUB307, there was no significant
230 change in anti-conjugal activity for benzyl isothiocyanate (**3**), and it surprisingly remained
231 active at the low concentrations tested. The observed conjugal transfer of pUB307 in the
232 presence of **3** ranged between 11.3±2.6% and 1.9±2.2% for concentrations of 0.125 and 64
233 mg/L, respectively.

234

235 **3.5. Effect of increasing concentration of 4-methoxyphenyl isothiocyanate (5) on conjugal**
236 *transfer of pUB307*

237 Among the test isothiocyanates, 4-methoxyphenyl isothiocyanate (5) was the most active
238 against IncP plasmid pUB307, with no plasmid curing activity. It was therefore evaluated for
239 the effect of increasing concentration (1-128 mg/L) on the conjugal transfer of plasmid
240 pUB307. The observed activities are shown in Figure 4. 4-methoxyphenyl isothiocyanate (5)
241 showed a moderate anti-conjugant activity ($22.7 \pm 1.6\%$) at the lowest concentration (1 mg/L)
242 and this was steadily maintained up to 32 mg/L, after which there was a sharp increase in
243 conjugal inhibition. Almost complete conjugal inhibition was observed at 128 mg/L.

244

245 **3.6. Effect of allyl (1) and benzyl (3) isothiocyanates on normal growth of human dermal**
246 *fibroblast, adult cells (HDFa; C-013-5C)*

247 Allyl (1) and benzyl (3) isothiocyanates that exhibited active to moderate anti-conjugant
248 activity against all test plasmids were further assessed for cytotoxicity against normal cell
249 growth. This was to determine whether the broad range anti-conjugant activity exhibited by
250 isothiocyanates 1 and 3 were not at cytotoxic concentrations and worth pursuing as potential
251 anti-conjugants for further development. The observed cytotoxic activities are shown in the
252 Figure 5. The IC_{50} for allyl (1) and benzyl (3) isothiocyanates against HDFa cells was 63.9
253 mg/L (645 μ M) and 30.3 mg/L (203 μ M), respectively.

254

255 **4. Discussion**

256 The discovery of a potent compound that will inhibit the spread of resistance genes and/or
257 resistance mechanisms has clinical relevance, especially in this era of plasmids within species
258 such as *K. pneumoniae* that are carbapenem-resistant. This is highly timely given the lack of
259 treatment options for infections caused by this pathogen. In line with this, selected

260 isothiocyanates, which are hydrolysis products of glucosinolates commonly found in *Brassica*
261 vegetables, were investigated for the possibility of inhibiting the spread of resistance genes by
262 blocking bacterial conjugation in *E. coli*.

263
264 The initial findings from this study showed that allyl isothiocyanate (**1**), L-sulforaphane (**2**),
265 benzyl isothiocyanate (**3**), phenylethyl isothiocyanate (**4**) and 4-methoxyphenyl
266 isothiocyanate (**5**) have some level of antibacterial activity that ranged from 16 to > 512 mg/L
267 against the susceptible *E. coli* NCTC 10418 and *S. aureus* ATCC 23925, and the effluxing
268 multidrug-resistant *S. aureus* strains (SA-1199B and XU212) (Table 1). This corroborates the
269 reported antibacterial activity of the isothiocyanates but due to the variability in the testing
270 methods, bacterial inoculum densities and diversity in susceptibility, it is difficult to compare
271 results [25-31]. The isothiocyanates were found to be less potent in comparison to
272 conventional antibiotics and similar results have been reported by others [25, 27, 31]. Among
273 the tested isothiocyanates, **4** was the most potent against the Gram-positive microbes with
274 MIC values ranging from 16 to 32 mg/L followed by **2** (MIC values ranged from 32 to 64
275 mg/L), which was also the most potent against Gram-negative *E. coli* NCTC 10418. The
276 antibacterial activity of these isothiocyanates have been explained to be due to their ability to
277 cause physical membrane damage [32, 33], interfere with bacterial redox system, which
278 affects the cell membrane potential [33] or the disruption of major metabolic processes [34,
279 35].

280 With the anti-conjugal activity study, broad-range anti-conjugant activity was observed for
281 allyl (**1**) and benzyl isothiocyanate (**3**) at sub-inhibitory concentrations, with **3** being the most
282 potent among the test isothiocyanates (Figure 1). It inhibited the conjugation of plasmids
283 pKM101 (IncN), TP114 (IncI₂) and pUB307 (IncP), and selectively cured plasmid TP114,
284 only. Against plasmids pKM101 and TP114, **3** also reduced conjugal transfer by 97.7±3.3%

285 and 96.4±4.2%, respectively at 32 mg/L (214.46 µM), and its activity gradually declined with
286 decreasing concentration (Figure 3). This was not the same for pUB307, where **3** continued to
287 show pronounced activity with a 90.8±2.3% reduction in conjugation, even at a low
288 concentration of 0.25 mg/L (1.68 µM). This was interesting, as **3** did not show any plasmid
289 curing activity against this particular plasmid pUB307 and pKM101, ruling out the fact that
290 the observed anti-conjugation may be due to plasmid elimination. Another area of interest was
291 that **3** exhibited broad-range activity; this could mean that **3** either acts on a common target
292 site on the conjugation machinery or that it causes general cell toxicity. However, considering
293 the MIC value (128 mg/L, Table 1) of **3** against the susceptible *E. coli* strain NCTC 10418,
294 the concentrations (\leq 32 mg/L) used for the conjugation assays were at sub-lethal doses and it
295 is less likely to have caused general cell toxicity. With allyl isothiocyanate (**1**), moderate
296 plasmid elimination activity was observed against most of the test plasmids and this may be
297 an indication that its broad-range anti-conjugant activity is due to plasmid curing. The broad-
298 range of activity of **1** and **3** prompted their testing against normal growth of human dermal
299 fibroblast, adult cells (HDFa; C-013-5C). A comparison of the cytotoxic value of **3** against
300 HDFa cells (30.30 mg/L; 203.07 µM) with its anti-conjugant concentration against the test
301 plasmids showed that its IC₅₀ level was above the concentrations needed to cause a 50%
302 reduction in conjugal transfer of plasmids; pKM101 (IC₅₀ = 2.19 mg/L; 14.68 µM), TP114
303 (IC₅₀ = 1.24 mg/L; 8.31 µM) and pUB307 (IC₅₀ = 0.34 mg/L; 2.28 µM) (Figure 5). This
304 suggests that **3** showed anti-conjugant activity at non-toxic concentrations. However, the
305 same cannot be said for compound **1** because, its IC₅₀ against HDFa (63.9 mg/L; 644.48 µM)
306 was below the 100 mg/L needed to cause moderate anti-conjugant activity (90-50%
307 reduction) against most of the test plasmids. It is therefore suggested that the concentrations
308 needed to cause a 50% reduction in conjugation is most likely to be closer to the cytotoxic-
309 IC₅₀ value.

310

311 From this study, specificity of anti-conjugal and plasmid curing activity was observed for 4-
312 methoxyphenyl isothiocyanate (**5**), a synthetic compound. L-sulforaphane (**2**) also exhibited
313 some level of anti-conjugant specificity against the IncW plasmid R7K at 16 mg/L (90.25
314 μM), but at this same concentration plasmid curing was observed and hence **2** is not a true
315 anti-conjugant (Figure 2). Compound **5**'s anti-conjugant activity at 100 mg/L (605.29 μM)
316 was pronounced for the IncP plasmid pUB307, with a $94.8 \pm 2.8\%$ reduction in conjugation,
317 but it showed minimal inhibition or promoted conjugation for the other test plasmids (Figure
318 1). Its anti-conjugant activity was however concentration-dependent (Figure 4). With the
319 plasmid curing effect, **5** showed elimination of only the IncW plasmid R7K, but it did not
320 have any effect on conjugation of this plasmid. This may give an indication that **5** could have
321 some conjugation promotion factors, and this was observed for pKM101. Conjugation of
322 pKM101 in the presence of **5** exceeded 100% (Figure 1). The anti-conjugation, plasmid
323 curing and pro-conjugation activity exhibited by **5** supports its specificity. This suggests that
324 compound **5** acts on a specific target site, which may not be common to all plasmids.
325 Consequently, it is less likely for resistance to develop against **5** unlike other compounds that
326 target general and essential targets of bacteria, which is the case in many instances of
327 antibiotic resistance [36]. A general observation with the test isothiocyanates is that the
328 presence of oxygen, attached to sulphur or an aromatic carbon conferred some level of anti-
329 conjugal specificity. We therefore hypothesize that the methoxyl substituent on the aromatic
330 ring and the lack of a hydrocarbon chain of **5**, which makes it structurally different from the
331 other test aromatic isothiocyanates, may have contributed to its specificity of activity.

332

333 In conclusion, isothiocyanate **3** and **5** were the most promising anti-conjugants identified in
334 this study. Further explorative studies involving structural modification and mechanistic

335 studies of these isothiocyanates could possibly lead to the identification of a potent anti-
336 conjugant. This will help decrease the spread of multidrug-resistant genes, multidrug resistant
337 bacteria, reduce virulence and help reinstate existing antibiotics.

338

339 **Declarations**

340 **Funding:** This work was funded by Commonwealth Scholarship Commission (CSC) (grant
341 number: GHCA-2012-19).

342 **Competing Interests:** None declared.

343 **Ethical Approval:** Not required.

344

345 **Supplementary material**

346 Supplementary material relating to this article has been attached.

347

348

349 **References**

- 350 [1] Fernandez-Lopez R, Machon C, Longshaw CM, Martin S, Molin S, Zechner EL, et al.
351 Unsaturated fatty acids are inhibitors of bacterial conjugation. *Microbiology*.
352 2005;151:3517-26.
- 353 [2] Zechner EL, Lang S, Schildbach JF. Assembly and mechanisms of bacterial type IV
354 secretion machines. *Philosophical Transactions of the Royal Society B*. 2012;367:1073-
355 87.
- 356 [3] DeNap JCB, Thomas JR, Musk DJ, Hergenrother PJ. Combating drug-resistant
357 bacteria: Small molecule mimics of plasmid incompatibility as antiplasmid compounds. *J*
358 *Am Chem Soc*. 2004;126:15402-4.
- 359 [4] Thomas JR, DeNap JCB, Wong ML, Hergenrother PJ. The relationship between
360 aminoglycosides' RNA binding proclivity and their antiplasmid effect on an IncB
361 plasmid. *Biochemistry*. 2005;44:6800-8.
- 362 [5] DeNap JCB, Hergenrother PJ. Bacterial death comes full circle: targeting plasmid
363 replication in drug-resistant bacteria. *Org Biomol Chem*. 2005;3:959-66.
- 364 [6] Moritz EM, Hergenrother PJ. Toxin-antitoxin systems are ubiquitous and plasmid-
365 encoded in vancomycin-resistant enterococci. *Proc Natl Acad Sci U S A*. 2007;104:311-6.
- 366 [7] Wang NR, Hergenrother PJ. A continuous fluorometric assay for the assessment of
367 MazF ribonuclease activity. *Anal Biochem*. 2007;371:173-83.
- 368 [8] Hilleringmann M, Pansegrau W, Doyle M, Kaufman S, MacKichan ML, Gianfaldoni C, et
369 al. Inhibitors of *Helicobacter pylori* ATPase Cagalpha block CagA transport and cag
370 virulence. *Microbiology*. 2006;152:2919-30.
- 371 [9] Backert S, Meyer TF. Type IV secretion systems and their effectors in bacterial
372 pathogenesis. *Curr Opin Microbiol*. 2006;9:207-17.

373 [10] Getino M, Sanabria-Rios DJ, Fernandez-Lopez R, Campos-Gomez J, Sanchez-Lopez
374 JM, Fernandez A, et al. Synthetic fatty acids prevent plasmid-mediated horizontal gene
375 transfer. MBio. 2015;6:1-8.

376 [11] Getino M, Fernandez-Lopez R, Palencia-Gandara C, Campos-Gomez J, Sanchez-Lopez
377 JM, Martinez M, et al. Tanzawaic acids, a chemically novel Set of bacterial conjugation
378 inhibitors. PLoS One. 2016;11:1-13.

379 [12] Mithen RF, Dekker M, Verkerk R, Rabot S, Johnson IT. The nutritional significance,
380 biosynthesis and bioavailability of glucosinolates in human foods. J Sci Food Agric.
381 2000;80:967 - 84.

382 [13] Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of
383 glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56:5-51.

384 [14] Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob
385 Chemother. 2001;48:5-16.

386 [15] San Millan A, MacLean RC. Fitness Costs of Plasmids: a Limit to Plasmid
387 Transmission. Microbiol Spectr. 2017;5.

388 [16] Kottara A, Hall JPJ, Harrison E, Brockhurst MA. Variable plasmid fitness effects and
389 mobile genetic element dynamics across *Pseudomonas* species. FEMS Microbiol Ecol.
390 2018;94:fix172-fix.

391 [17] Oyedemi BOM, Shinde V, Shinde K, Kakalou D, Stapleton PD, Gibbons S. Novel R-
392 plasmid conjugal transfer inhibitory and antibacterial activities of phenolic compounds
393 from *Mallotus philippensis* (Lam.) Mull. Arg. Journal of Global Antimicrobial Resistance.
394 2016;5:15-21.

395 [18] Kwapong AA, Stapleton P, Gibbons S. A new dimeric imidazole alkaloid plasmid
396 conjugation inhibitor from *Lepidium sativum*. Tetrahedron Lett. 2018;59:1952-4.

397 [19] Rice LB, Bonomo RA. Genetic and biochemical mechanisms of bacterial resistance to
398 antimicrobial agents. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed.
399 USA: Lippincott Williams & Wilkins; 2005. p. 483-4.

400 [20] Hooper DC, Wolfson JS, McHugh GL, Swartz MD, Tung C, Swartz MN. Elimination of
401 plasmid pMG110 from *Escherichia coli* by novobiocin and other inhibitors of DNA
402 gyrase. Antimicrob Agents Chemother. 1984;25:586-90.

403 [21] Molnar A. Antiplasmid effect of promethazine in mixed bacterial cultures. Int J
404 Antimicrob Agents. 2003;22:217-22.

405 [22] Splenger G, Molnar A, Schelz Z, Amaral L, Sharples D, Molnar J. The mechanism of
406 plasmid curing in bacteria. Curr Drug Targets. 2006;7:1389-4501.

407 [23] Molnar J, Mandi Y, Splenger G, Amaral L, Haszon I, Turi S, et al. Synergism between
408 antiplasmid promethazine and antibiotics *in vitro* and *in vivo*. Mol Biol. 2014;04:1-6.

409 [24] Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New
410 colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst.
411 1990;82:1107-12.

412 [25] Romeo L, Iori R, Rollin P, Bramanti P, Mazzon E. Isothiocyanates: An overview of
413 their antimicrobial activity against human infections. Molecules. 2018;23:1-18.

414 [26] Dufour V, Stahl M, Baysse C. The antibacterial properties of isothiocyanates.
415 Microbiology. 2015;161:229-43.

416 [27] Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al.
417 Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of
418 *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl
419 Acad Sci U S A. 2002;99:7610-15.

420 [28] Kim MG, Lee HS. Growth-inhibiting activities of phenethyl isothiocyanate and its
421 derivatives against intestinal bacteria. J Food Sci. 2009;74:M467-M71.

422 [29] Borges A, Abreu AC, Ferreira C, Saavedra MJ, Simoes LC, Simoes M. Antibacterial
423 activity and mode of action of selected glucosinolate hydrolysis products against
424 bacterial pathogens. J Food Sci Technol. 2015;52:4737-48.

425 [30] Nowicki D, Rodzik O, Herman-Antosiewicz A, Szalewska-Pałasz A. Isothiocyanates
426 as effective agents against enterohemorrhagic *Escherichia coli*: insight to the mode of
427 action. Sci Rep. 2016;6:1-12.

428 [31] Lu Z, Dockery CR, Crosby M, Chavarria K, Patterson B, Giedd M. Antibacterial
429 Activities of Wasabi against *Escherichia coli* O157:H7 and *Staphylococcus aureus*. Front
430 Microbiol. 2016;7:1-9.

431 [32] Lin CM, Preston III JF, Wei CI. Antibacterial mechanism of allyl isothiocyanate. J
432 Food Prot. 2000;63:727-34.

433 [33] Sofrata A, Santangelo EM, Azeem M, Borg-Karlson AK, Gustafsson A, Pütsep K.
434 Benzyl isothiocyanate, a major component from the roots of *Salvadora Persica* is highly
435 active against Gram-negative bacteria. PLoS One. 2011;6:1-10.






436 [34] Abreu AC, Borges A, Simoes LC, Saavedra MJ, Simoes M. Antibacterial activity of
437 phenyl isothiocyanate on *Escherichia coli* and *Staphylococcus aureus*. Medicinal
438 Chemistry. 2013;9:756-61.

439 [35] Dufour V, Stahl M, Rosenfeld E, Stintzi A, Baysse C. Insights into the mode of action
440 of benzyl isothiocyanate on *Campylobacter jejuni*. Appl Environ Microbiol.
441 2013;79:6958-68.

442 [36] Smith PA, Romesberg FE. Combating bacteria and drug resistance by inhibiting
443 mechanisms of persistence and adaptation. Nat Chem Biol. 2007;3:549-56.

444

Table 1. Minimum inhibitory concentration (MIC) values against *E. coli* and *S. aureus*

Isothiocyanate (sample number)	Chemical Structure	MIC (mg/L)			
		<i>E. coli</i> NCTC 10418 ^a	<i>S. aureus</i> ATCC 25923 ^a	<i>S. aureus</i> SA- 1199B ^b	<i>S. aureus</i> XU212 ^c
Allyl isothiocyanate (1)		> 512	512	512	> 512
L-sulforaphane (2)		64	64	32	32
Benzyl isothiocyanate (3)		128	256	256	512
Phenylethyl isothiocyanate (4)		256	16	32	32
4- methoxyphenyl isothiocyanate (5)		512	256	128	128
Ciprofloxacin	-	< 0.0625	< 0.0625	-	-
Norfloxacin	-	-	-	32	-
Tetracycline	-	-	-	-	128

^a susceptible standard strain, ^b fluoroquinolone-resistant strain that over-expresses the NorA efflux pump and ^c tetracycline-resistant strain, which over-expresses the TetK efflux pump.




Fig 1. The effect of selected isothiocyanates on the conjugal transfer of: (A) IncN plasmid pKM101, (B) IncI₂ plasmid TP114 (C) IncP plasmid pUB307 and (D) IncW plasmid R7K, expressed as a percentage relative to a control (Ctl, without a test compound). The isothiocyanates were tested at sub-inhibitory concentrations: allyl isothiocyanate (1, 100 mg/L), L-sulforaphane (2, 16 mg/L), benzyl isothiocyanate (3, 32 mg/L), phenylethyl isothiocyanate (4, 64 mg/L) and 4-methoxyphenyl isothiocyanate (5, 100 mg/L). Linoleic acid (6), a known anti-conjugant for IncW plasmids was tested at 200 mg/L. Values represent means \pm standard deviations of at least three independent experiments measured by the plate conjugation assay. *, $P < 0.05$ (was significantly different from the control).

Figure 2




Fig 2. Plasmid elimination activity of the isothiocyanates. The isothiocyanates were tested at concentrations: allyl isothiocyanate (**1**, 100 mg/L), L-sulforaphane (**2**, 16 mg/L), benzyl isothiocyanate (**3**, 32 mg/L), phenylethyl isothiocyanate (**4**, 64 mg/L), 4-methoxyphenyl isothiocyanate (**5**, 100 mg/L) and promethazine (**Pmz**, 16 mg/L).

Figure 3




Fig 3. The effect of increasing concentration of benzyl isothiocyanate (**3**) on the conjugal transfer of plasmids pKM101 (IncN), TP114 (IncI₂) and pUB307 (IncP) relative to a control, without test sample (100% conjugation frequency). The values represent the mean \pm SD of a least three independent experiments measured by plate conjugation assay.

Figure 4




Fig 4. The effect of increasing concentration of 4-methoxyphenyl isothiocyanate (**5**) on the conjugal transfer of IncP plasmid pUB307 relative to a control, without test sample (100% conjugation frequency). The values represent the mean \pm SD of a least three independent experiments measured by plate conjugation assay.

Figure 5




Fig 5. The effect of allyl (1) and benzyl (3) isothiocyanates on growth HDFa; C-013-5C. The values represent the mean \pm SD of a least three independent experiments measured by cytotoxicity assay.

Supplementary data

[Click here to download Supplementary data: Supplementary data.doc](#)

14 **Abstract**

15 Bacterial conjugation is the main mechanism for the transfer of multiple antibiotic resistance
16 genes among pathogenic microorganisms. This process could be controlled by compounds
17 that inhibit bacterial conjugation. In this study, the effect of allyl isothiocyanate, L-
18 sulforaphane, benzyl isothiocyanate, phenylethyl isothiocyanate and 4-methoxyphenyl
19 isothiocyanate on the conjugation of broad host range plasmids, which harbor various
20 resistance genes in *Escherichia coli* were investigated; pKM101 (IncN), TP114 (IncI₂),
21 pUB307 (IncP) and the low copy number IncW plasmid R7K. Benzyl isothiocyanate (32
22 mg/L) significantly reduced the conjugal transfer of pKM101, TP114 and pUB307 to
23 0.3±0.6%, 10.7±3.3% and 6.5±1.0%, respectively. L-sulforaphane (16 mg/L, transfer
24 frequency 21.5±5.1%) and 4-methoxyphenyl isothiocyanate (100 mg/L, transfer frequency
25 5.2±2.8%) were the only compounds that showed anti-conjugal specificity by actively
26 reducing the transfer of R7K and pUB307, respectively.

27

28 **Keywords:** Isothiocyanates, bacterial conjugation, conjugative plasmids, effector proteins,
29 horizontal gene transfer, plasmid incompatibility groups

30

31

32 **1. Introduction**

33 Bacterial conjugation is an adaptive mechanism that allows bacteria to transfer genetic
34 materials, effector proteins and/or toxins from one cell to the other through a conjugative
35 bridge [1, 2]. The genetic materials that are transferred via conjugation usually confer
36 selective advantages to the recipient organism, such as survival, resistance, pathogenicity,
37 infection activities and/or the ability to respond to environmental changes. Conjugation
38 greatly increases bacterial genome plasticity, and has immense clinical relevance as a major
39 route for the spread of multiple antibiotic resistance genes among the microbial community
40 and virulence genes from pathogen to host [2]. It is therefore imperative to find ways to
41 combat conjugation, as a means to decrease the ongoing rise of antibiotic-resistant infections.

42

43 Inhibition of bacterial conjugation has not received much research attention because the focus
44 has been on the identification of new classes of antibacterial agents that target processes
45 essential for bacterial growth such as cell wall biosynthesis, the cell membrane, protein
46 synthesis, nucleic acid synthesis and metabolite activity. This traditional approach has
47 produced many therapeutically useful agents so far, but the challenge is that an antibiotic also
48 introduces selective pressure promoting resistant bacteria, and therefore this has led to the
49 current antibiotic resistance crisis. An additional approach of reducing the increasing rate of
50 bacterial antibiotic resistance dissemination and re-sensitizing bacteria to existing antibiotics,
51 would be to target non-essential processes such as conjugation, which are less likely to evoke
52 bacterial resistance. This approach could also have a prophylactic use in cosmeceuticals to
53 reduce plasmid transfer. In addition to bacterial conjugation, other non-essential processes
54 **such as plasmid replication** [3-5] and plasmid-encoded toxin-antitoxin systems [6, 7] have
55 been exploited with promising potential in antibacterial therapy.

56 The few efforts directed towards identifying anti-conjugants include small-molecule
57 inhibitors of *Helicobacter pylori* *cag* VirB11-type ATPase Cag α [8]. The *cag* genes encode
58 for the assembly of the conjugative bridge and injection of the CagA toxin into host cells [8,
59 9]. In addition, there have been other reports of promising anti-conjugants such as
60 dehydrocrepenynic acid [1], linoleic acid [1], 2-hexadecanoic acid [10], 2-octadecanoic acid
61 [10], and tanzawaic acids A and B [11]. However, these compounds have stability, toxicity or
62 scarcity issues that need to be addressed. Therefore there is the pressing need to identify safer
63 anti-conjugants to help in the fight against plasmid-mediated transfer and spread of antibiotic
64 resistance and virulence.

65
66 In this study, four naturally occurring isothiocyanates (allyl isothiocyanate (**1**), L-
67 sulforaphane (**2**), benzyl isothiocyanate (**3**), phenylethyl isothiocyanate (**4**)) and a synthetic
68 isothiocyanate (4-methoxyphenyl isothiocyanate, **5**) were investigated for their anti-conjugant
69 activity against *E. coli* strains bearing conjugative plasmids with specific antibiotic resistance
70 genes. Isothiocyanates are usually naturally occurring hydrolytic products of glucosinolates,
71 which are commonly found in the *Brassica* vegetables. They are produced when damaged
72 plant tissue releases the glycoprotein enzyme myrosinase, which hydrolyses the β -glucosyl
73 moiety of a glucosinolate. This leaves the unstable aglycone, thiohydroxamate-*O*-sulfonate,
74 which rearranges to form an isothiocyanate or other breakdown products [12, 13]. Other
75 isothiocyanates such as 4-methoxyphenyl isothiocyanate and methyl isothiocyanate are
76 synthetically produced and not naturally occurring.

77
78 In addition to the anti-conjugant testing, plasmid curing activity and bacterial growth
79 inhibition were also evaluated to help **discriminate** between true anti-conjugants and
80 substances that reduce conjugation due to elimination of plasmids or function by perturbation

81 of bacterial growth or physiology. Isothiocyanates possessing the highest anti-conjugant
82 activities were further investigated for cytotoxicity against human dermal fibroblast adult
83 cells (HDFa; C-013-5C).

84

85

86 **2. Materials and methods**

87 *2.1. Bacterial strains and plasmids*

88 *E. coli* NCTC 10418 (a susceptible Gram-negative strain), *S. aureus* ATCC 25923 (a
89 susceptible Gram-positive strain), *S. aureus* SA-1199B (a fluoroquinolone-resistant strain,
90 which over-expresses the multidrug-resistant NorA pump) and *S. aureus* XU212 (a
91 tetracycline-resistant strain, which over-expresses the multidrug-resistant TetK pump) were
92 used for the broth dilution assay. Plasmid-containing *E. coli* strains WP2, K12 J53-2 and K12
93 JD173 were used as donor strains in the plate conjugation and plasmid elimination assays. *E.*
94 *coli* ER1793 (streptomycin-resistant) and *E. coli* JM109 (nalidixic-resistant) were used as the
95 recipients. Conjugative plasmids used were pKM101 (WP2; incompatibility group N (IncN);
96 ampicillin-resistant), TP114 (K12 J53-2; IncI₂; kanamycin-resistant), and R7K (K12 J53-2;
97 IncW; ampicillin-, streptomycin- and spectinomycin-resistant), which were purchased from
98 Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and conjugative
99 plasmid pUB307 (K12 JD173; IncP; ampicillin-, kanamycin- and tetracycline-resistant) was
100 provided by Prof. Keith Derbyshire, Wadsworth Center, New York Department of Health.

101

102 *2.2. Broth micro-dilution assay*

103 The antibacterial activity was determined with the broth micro-dilution method as described
104 previously [14], which is a modified version of the procedure described in the British
105 Society for Antimicrobial Chemotherapy (BSAC) guide to sensitivity testing. Bacteria were
106 cultured on nutrient agar slants and incubated at 37°C for 18 hours. A bacterial suspension
107 equivalent to a 0.5 McFarland standard was made from the overnight culture. This was added
108 to Muller-Hinton broth and the test isothiocyanate, which had been serially diluted across a
109 96-well microtitre plate, to achieve a final inoculum of 0.5×10^5 CFU/mL. Minimum

110 inhibitory concentrations (MICs) were determined after 18 hours of incubation at 37°C. This
111 was done by visual inspection after the addition of a 1 mg/mL methanolic solution of 3-[4,5-
112 dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and incubation at 37°C for 20
113 minutes. This experiment was performed in duplicate in two independent experiments.

114

115 2.3. Liquid conjugation assay

116 The donor cells with plasmids pKM101, TP114 and pUB307 were paired with the recipient
117 ER1793. Plasmid R7K donor cells were paired with the recipient JM109. Research has shown
118 that plasmid carriage by host bacteria is associated with some fitness cost (burden) [15, 16].
119 This fitness effect of plasmids plays a vital role in their ability to associate with a new
120 bacterial host. As a consequence of this we selected different *E. coli* host, which are known to
121 successfully conjugate [17, 18] and to maintain the study plasmids. The liquid conjugation
122 assay was performed as previously described [19] with slight modifications. Equal volumes
123 (20 µL) of donor and recipient, for which the colony forming units per mL (CFU/mL) had
124 been predetermined (Supplementary Table 1), were introduced into 160 µL of Luria-Bertani
125 broth and the test sample or control. This was incubated at 37°C for 18 hours after which the
126 number of transconjugants and donor cell were determined using antibiotic-containing
127 MacConkey agar plates. A positive control linoleic acid [1] and negative control (donor,
128 recipient and media; without drug or test sample) were included in the experiment. The
129 isothiocyanates were evaluated for anti-conjugant activity at sub-inhibitory concentration
130 (one-quarter of the MIC). Antibiotics were added at the following concentrations for positive
131 identification of donors, recipients and transconjugants (mg/L): amoxicillin (30),
132 streptomycin sulphate (20), nalidixic acid (30), kanamycin sulphate (30). Conjugation
133 frequencies were calculated as the ratio of total number of transconjugants (cfu/mL) to the
134 total number of donor (cfu/mL) and expressed as a percentage relative to the negative control.

135 This experiment was performed as duplicate in three independent experiments and anti-
136 conjugation activity is reported as the mean \pm standard deviation.

137

138 2.4. Plasmid elimination assay

139 This assay was performed as described previously [20] with minor modifications. The *E. coli*
140 donor strains were sub-cultured on appropriate antibiotic-containing MacConkey agar plates
141 to ensure plasmid presence. After incubation of the plates at 37°C for 18 hours, single
142 colonies (2-3) were selected and inoculated into LB. This was incubated for 18 h at 37°C and
143 the colony forming units were determined prior to the assay. Twenty microliters of the
144 overnight culture was then added to a mixture of 180 μ L LB and test sample in a 96 well
145 microtitre plate. This was incubated overnight (18 h) at 37°C and subsequently serially
146 diluted, 20 μ L was then plated on antibiotic containing MacConkey agar and incubated for 18
147 h at 37°C. The isothiocyanates were evaluated for plasmid elimination activity at
148 concentrations used in the liquid conjugation assay. Both positive control (promethazine) [21-
149 23] and negative control (mixture without isothiocyanate or control drug) were included in
150 this experiment. Plasmid elimination was calculated using:

$$151 \text{ Plasmid elimination} = \frac{\text{CFU/mL of control} - \text{CFU/mL of test sample}}{\text{CFU/mL of control}} \times 100$$

152 Antibiotics and concentrations used in MacConkey agar for positive identification of *E. coli*
153 cells harbouring plasmids (mg/L) were: amoxicillin (30), kanamycin sulphate (20 and 30) and
154 nalidixic acid (30). This experiment was performed in duplicate, with three independent
155 experiments.

156

157 2.5. Cytotoxicity assay

158 The isothiocyanates that showed anti-conjugant activity were further assessed for their effect
159 on eukaryotic cell growth. The sulforhodamine B (SRB) colorimetric assay as described

160 previously [24] was used, with modifications. Human dermal fibroblast, adult cells (HDFa; C-
161 013-5C) were grown in a 75 cm² culture flask at 37°C in humidified atmosphere of 5%
162 carbon dioxide using Dulbecco's Modified Eagle's Medium, which was supplemented with
163 10% fetal bovine serum (FBS), 1% non-essential amino acids, 0.1% gentamicin and
164 amphotericin B. The grown cells were seeded in a 96 well microtitre plated and test samples
165 and media were added. This was then incubated at 37°C in 5% CO₂ for 72 h. Afterwards 50
166 μL of cold 40% ^{W/V} trichloroacetic acid (TCA) solution was added, the plate was placed in
167 the fridge for an hour at 4°C and washed four times with distilled water. The cells were then
168 stained with 0.4% ^{W/V} SRB solution and left at room temperature for an hour. Afterwards, the
169 plate was rinsed four times with 1% acetic acid and left overnight (24 h) to dry. Thereafter,
170 100 μL of 10 mM Tris buffer solution was dispensed into the wells and agitated in an orbital
171 shaker for 5 min, to allow solubilisation of SRB-protein complex. The optical density (OD)
172 was then measured at 510 nm using a microtitre plate reader (Tecan Infinite® M200). The
173 percentage of viable cell was calculated using:

174

$$\text{Percentage of viable cell} = \frac{\text{OD of test sample} - \text{OD of blank}}{\text{OD of negative control} - \text{OD of blank}} \times 100$$

176

177 This experiment was performed as triplicate in three independent experiments and
178 cytotoxicity has been reported as mean ± standard deviation.

179

180 2.6. Statistical analyses

181 The statistical analyses were carried out using Excel Data Analysis and GraphPad Prism 7.

182 Welch's t-test was used to evaluate the difference between the control conjugal transfer

183 frequency and the test compounds. Results with $p < 0.05$ were considered statistically

184 significant.

185

186 **3. Results**

187 *3.1. The effect of isothiocyanates on the growth of bacteria*

188 To test whether the selected isothiocyanates had growth inhibitory activity against bacterial
189 species and to inform of a suitable concentration for their evaluation in an anti-conjugation
190 assay, the isothiocyanates were tested against susceptible Gram-negative (*E. coli* NCTC
191 10418) and Gram-positive (*S. aureus* ATCC 25923) standard isolates, and antibiotic effluxing
192 *Staphylococcus aureus* strains (SA-1199B and XU212). Table 1 shows the MIC values for the
193 tested isothiocyanates; their inhibitory activity varied from 16 to 512 mg/L against the
194 evaluated bacteria. Our general observation was that unsurprisingly the isothiocyanates were
195 marginally more active against the Gram-positive than the Gram-negative strains.

196

197 *3.2. The effect of isothiocyanates on conjugal transfer of plasmids*

198 To investigate whether the selected isothiocyanates have anti-conjugant activity, a range of
199 plasmids belonging to different incompatibility groups (IncN plasmid pKM101, IncI₂ plasmid
200 TP114, IncP plasmid pUB307 and IncW plasmid R7K) were employed to test the specificity
201 of conjugation inhibition in *E. coli*. With information (Table 1) about their minimum
202 inhibitory concentration against *E. coli* NCTC 10418 (a susceptible standard strain), the
203 isothiocyanates were tested at a sub-inhibitory concentration, one-quarter of their MICs.
204 Figure 1 shows the effect of the isothiocyanates on the conjugal transfer of the test plasmids.
205 The test isothiocyanates exhibited inhibitory activities ranging from complete reduction in
206 conjugation frequency (0%, considered active), inhibition of conjugation frequency to less
207 than 10% were also considered as active; 10 to 50% were considered moderately active and
208 greater than 50% were considered as inactive.

209

210 *3.3. Elimination of plasmids from E. coli*

211 To determine whether the observed anti-conjugant activity was not due to the elimination of
212 conjugative plasmids, the donor cells were grown in the presence of the test isothiocyanates,
213 and the plasmid elimination assay was performed. **Figure 2** shows the effect of the
214 isothiocyanates on conjugative plasmids. The isothiocyanates exhibited varied plasmid curing
215 activity. Plasmids TP114 and R7K of the incompatibility groups I₂ and P, respectively, were
216 the most eliminated in the donor cells with elimination percentages ranging from 3.0±0.1 to
217 77.8±8.0. Most of the tested isothiocyanates did not have any plasmid curing effects on
218 pKM101 (IncN), with the exception of allyl isothiocyanate (**1**), which showed a curing effect
219 of 19.4±6.6 %. For pUB307 (IncP), a plasmid curing effect was observed for L-sulforaphane
220 (**2**, 56.7±3.2 %) and phenylethyl isothiocyanate (**4**, 64.8±15.4 %).

221

222 *3.4. The effect of increasing concentration of benzyl isothiocyanate (3) on conjugal transfer*
223 *of the plasmids pKM101 (IncN), TP114 (IncI₂) and pUB307 (IncP)*

224 With benzyl isothiocyanate (**3**) having shown broad range anti-conjugant (conjugal reduction
225 to 0.3±0.6 - 10.7±3.3%, Figure 1) and the least donor plasmid elimination activity (0 -
226 26.5±5.9%, Figure 2) of all tested compounds, it was further assessed to observe its effect on
227 conjugal transfer with increasing concentration. Generally, there was a gradual increase in
228 anti-conjugal activity against pKM101 and TP114 with increase in concentration from 0.125
229 to 64 mg/L (Figure 3). This was not the same for plasmid pUB307, there was no significant
230 change in anti-conjugal activity for benzyl isothiocyanate (**3**), and it surprisingly remained
231 **active at the low concentrations tested**. The observed conjugal transfer of pUB307 in the
232 presence of **3** ranged between 11.3±2.6% and 1.9±2.2% for concentrations of 0.125 and 64
233 mg/L, respectively.

234

235 **3.5. Effect of increasing concentration of 4-methoxyphenyl isothiocyanate (5) on conjugal**
236 *transfer of pUB307*

237 Among the test isothiocyanates, 4-methoxyphenyl isothiocyanate (5) was the most active
238 against IncP plasmid pUB307, with no plasmid curing activity. It was therefore evaluated for
239 the effect of increasing concentration (1-128 mg/L) on the conjugal transfer of plasmid
240 pUB307. The observed activities are shown in Figure 4. 4-methoxyphenyl isothiocyanate (5)
241 showed a moderate anti-conjugant activity ($22.7 \pm 1.6\%$) at the lowest concentration (1 mg/L)
242 and this was steadily maintained up to 32 mg/L, after which there was a sharp increase in
243 conjugal inhibition. Almost complete conjugal inhibition was observed at 128 mg/L.

244

245 **3.6. Effect of allyl (1) and benzyl (3) isothiocyanates on normal growth of human dermal**
246 *fibroblast, adult cells (HDFa; C-013-5C)*

247 Allyl (1) and benzyl (3) isothiocyanates that exhibited active to moderate anti-conjugant
248 activity against all test plasmids were further assessed for cytotoxicity against normal cell
249 growth. This was to determine whether the broad range anti-conjugant activity exhibited by
250 isothiocyanates 1 and 3 were not at cytotoxic concentrations and worth pursuing as potential
251 anti-conjugants for further development. The observed cytotoxic activities are shown in the
252 Figure 5. The IC_{50} for allyl (1) and benzyl (3) isothiocyanates against HDFa cells was 63.9
253 mg/L (645 μ M) and 30.3 mg/L (203 μ M), respectively.

254

255 **4. Discussion**

256 The discovery of a potent compound that will inhibit the spread of resistance genes and/or
257 resistance mechanisms has clinical relevance, especially in this era of plasmids within species
258 such as *K. pneumoniae* that are carbapenem-resistant. This is highly timely given the lack of
259 treatment options for infections caused by this pathogen. In line with this, selected

260 isothiocyanates, which are hydrolysis products of glucosinolates commonly found in *Brassica*
261 vegetables, were investigated for the possibility of inhibiting the spread of resistance genes by
262 blocking bacterial conjugation in *E. coli*.

263
264 The initial findings from this study showed that allyl isothiocyanate (**1**), L-sulforaphane (**2**),
265 benzyl isothiocyanate (**3**), phenylethyl isothiocyanate (**4**) and 4-methoxyphenyl
266 isothiocyanate (**5**) have some level of antibacterial activity that ranged from 16 to > 512 mg/L
267 against the susceptible *E. coli* NCTC 10418 and *S. aureus* ATCC 23925, and the effluxing
268 multidrug-resistant *S. aureus* strains (SA-1199B and XU212) (Table 1). This corroborates the
269 reported antibacterial activity of the isothiocyanates but due to the variability in the testing
270 methods, bacterial inoculum densities and diversity in susceptibility, it is difficult to compare
271 results [25-31]. The isothiocyanates were found to be less potent in comparison to
272 conventional antibiotics and similar results have been reported by others [25, 27, 31]. Among
273 the tested isothiocyanates, **4** was the most potent against the Gram-positive microbes with
274 MIC values ranging from 16 to 32 mg/L followed by **2** (MIC values ranged from 32 to 64
275 mg/L), which was also the most potent against Gram-negative *E. coli* NCTC 10418. The
276 antibacterial activity of these isothiocyanates have been explained to be due to their ability to
277 cause physical membrane damage [32, 33], interfere with bacterial redox system, which
278 affects the cell membrane potential [33] or the disruption of major metabolic processes [34,
279 35].

280 With the anti-conjugal activity study, broad-range anti-conjugant activity was observed for
281 allyl (**1**) and benzyl isothiocyanate (**3**) at sub-inhibitory concentrations, with **3** being the most
282 potent among the test isothiocyanates (Figure 1). It inhibited the conjugation of plasmids
283 pKM101 (IncN), TP114 (IncI₂) and pUB307 (IncP), and selectively cured plasmid TP114,
284 only. Against plasmids pKM101 and TP114, **3** also reduced conjugal transfer by 97.7±3.3%

285 and 96.4±4.2%, respectively at 32 mg/L (214.46 µM), and its activity gradually declined with
286 decreasing concentration (Figure 3). This was not the same for pUB307, where **3** continued to
287 show pronounced activity with a 90.8±2.3% reduction in conjugation, even at a low
288 concentration of 0.25 mg/L (1.68 µM). This was interesting, as **3** did not show any plasmid
289 curing activity against this particular plasmid pUB307 and pKM101, ruling out the fact that
290 the observed anti-conjugation may be due to plasmid elimination. Another area of interest was
291 that **3** exhibited broad-range activity; this could mean that **3** either acts on a common target
292 site on the conjugation machinery or that it causes general cell toxicity. However, considering
293 the MIC value (128 mg/L, Table 1) of **3** against the susceptible *E. coli* strain NCTC 10418,
294 the concentrations (\leq 32 mg/L) used for the conjugation assays were at sub-lethal doses and it
295 is less likely to have caused general cell toxicity. With allyl isothiocyanate (**1**), moderate
296 plasmid elimination activity was observed against most of the test plasmids and this may be
297 an indication that its broad-range anti-conjugant activity is due to plasmid curing. The broad-
298 range of activity of **1** and **3** prompted their testing against normal growth of human dermal
299 fibroblast, adult cells (HDFa; C-013-5C). A comparison of the cytotoxic value of **3** against
300 HDFa cells (30.30 mg/L; 203.07 µM) with its anti-conjugant concentration against the test
301 plasmids showed that its IC₅₀ level was above the concentrations needed to cause a 50%
302 reduction in conjugal transfer of plasmids; pKM101 (IC₅₀ = 2.19 mg/L; 14.68 µM), TP114
303 (IC₅₀ = 1.24 mg/L; 8.31 µM) and pUB307 (IC₅₀ = 0.34 mg/L; 2.28 µM) (Figure 5). This
304 suggests that **3** showed anti-conjugant activity at non-toxic concentrations. However, the
305 same cannot be said for compound **1** because, its IC₅₀ against HDFa (63.9 mg/L; 644.48 µM)
306 was below the 100 mg/L needed to cause moderate anti-conjugant activity (90-50%
307 reduction) against most of the test plasmids. It is therefore suggested that the concentrations
308 needed to cause a 50% reduction in conjugation is most likely to be closer to the cytotoxic-
309 IC₅₀ value.

310

311 From this study, specificity of anti-conjugal and plasmid curing activity was observed for 4-
312 methoxyphenyl isothiocyanate (**5**), a synthetic compound. L-sulforaphane (**2**) also exhibited
313 some level of anti-conjugant specificity against the IncW plasmid R7K at 16 mg/L (90.25
314 μM), but at this same concentration plasmid curing was observed and hence **2** is not a true
315 anti-conjugant (Figure 2). Compound **5**'s anti-conjugant activity at 100 mg/L (605.29 μM)
316 was pronounced for the IncP plasmid pUB307, with a $94.8 \pm 2.8\%$ reduction in conjugation,
317 but it showed minimal inhibition or promoted conjugation for the other test plasmids (Figure
318 1). Its anti-conjugant activity was however concentration-dependent (Figure 4). With the
319 plasmid curing effect, **5** showed elimination of only the IncW plasmid R7K, but it did not
320 have any effect on conjugation of this plasmid. This may give an indication that **5** could have
321 some conjugation promotion factors, and this was observed for pKM101. Conjugation of
322 pKM101 in the presence of **5** exceeded 100% (Figure 1). The anti-conjugation, plasmid
323 curing and pro-conjugation activity exhibited by **5** supports its specificity. This suggests that
324 compound **5** acts on a specific target site, which may not be common to all plasmids.
325 Consequently, it is less likely for resistance to develop against **5** unlike other compounds that
326 target general and essential targets of bacteria, which is the case in many instances of
327 antibiotic resistance [36]. A general observation with the test isothiocyanates is that the
328 presence of oxygen, attached to sulphur or an aromatic carbon conferred some level of anti-
329 conjugal specificity. We therefore hypothesize that the methoxyl substituent on the aromatic
330 ring and the lack of a hydrocarbon chain of **5**, which makes it structurally different from the
331 other test aromatic isothiocyanates, may have contributed to its specificity of activity.

332

333 In conclusion, isothiocyanate **3** and **5** were the most promising anti-conjugants identified in
334 this study. Further explorative studies involving structural modification and mechanistic

335 studies of these isothiocyanates could possibly lead to the identification of a potent anti-
336 conjugant. This will help decrease the spread of multidrug-resistant genes, multidrug resistant
337 bacteria, reduce virulence and help reinstate existing antibiotics.

338

339 **Declarations**

340 **Funding:** This work was funded by Commonwealth Scholarship Commission (CSC) (grant
341 number: GHCA-2012-19).

342 **Competing Interests:** None declared.

343 **Ethical Approval:** Not required.

344

345 **Supplementary material**

346 Supplementary material relating to this article has been attached.

347

348

349 **References**

- 350 [1] Fernandez-Lopez R, Machon C, Longshaw CM, Martin S, Molin S, Zechner EL, et al.
351 Unsaturated fatty acids are inhibitors of bacterial conjugation. *Microbiology*.
352 2005;151:3517-26.
- 353 [2] Zechner EL, Lang S, Schildbach JF. Assembly and mechanisms of bacterial type IV
354 secretion machines. *Philosophical Transactions of the Royal Society B*. 2012;367:1073-
355 87.
- 356 [3] DeNap JCB, Thomas JR, Musk DJ, Hergenrother PJ. Combating drug-resistant
357 bacteria: Small molecule mimics of plasmid incompatibility as antiplasmid compounds. *J*
358 *Am Chem Soc*. 2004;126:15402-4.
- 359 [4] Thomas JR, DeNap JCB, Wong ML, Hergenrother PJ. The relationship between
360 aminoglycosides' RNA binding proclivity and their antiplasmid effect on an IncB
361 plasmid. *Biochemistry*. 2005;44:6800-8.
- 362 [5] DeNap JCB, Hergenrother PJ. Bacterial death comes full circle: targeting plasmid
363 replication in drug-resistant bacteria. *Org Biomol Chem*. 2005;3:959-66.
- 364 [6] Moritz EM, Hergenrother PJ. Toxin-antitoxin systems are ubiquitous and plasmid-
365 encoded in vancomycin-resistant enterococci. *Proc Natl Acad Sci U S A*. 2007;104:311-6.
- 366 [7] Wang NR, Hergenrother PJ. A continuous fluorometric assay for the assessment of
367 MazF ribonuclease activity. *Anal Biochem*. 2007;371:173-83.
- 368 [8] Hilleringmann M, Pansegrau W, Doyle M, Kaufman S, MacKichan ML, Gianfaldoni C, et
369 al. Inhibitors of *Helicobacter pylori* ATPase Cagalpha block CagA transport and cag
370 virulence. *Microbiology*. 2006;152:2919-30.
- 371 [9] Backert S, Meyer TF. Type IV secretion systems and their effectors in bacterial
372 pathogenesis. *Curr Opin Microbiol*. 2006;9:207-17.

373 [10] Getino M, Sanabria-Rios DJ, Fernandez-Lopez R, Campos-Gomez J, Sanchez-Lopez
374 JM, Fernandez A, et al. Synthetic fatty acids prevent plasmid-mediated horizontal gene
375 transfer. MBio. 2015;6:1-8.

376 [11] Getino M, Fernandez-Lopez R, Palencia-Gandara C, Campos-Gomez J, Sanchez-Lopez
377 JM, Martinez M, et al. Tanzawaic acids, a chemically novel Set of bacterial conjugation
378 inhibitors. PLoS One. 2016;11:1-13.

379 [12] Mithen RF, Dekker M, Verkerk R, Rabot S, Johnson IT. The nutritional significance,
380 biosynthesis and bioavailability of glucosinolates in human foods. J Sci Food Agric.
381 2000;80:967 - 84.

382 [13] Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of
383 glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56:5-51.

384 [14] Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob
385 Chemother. 2001;48:5-16.

386 [15] San Millan A, MacLean RC. Fitness Costs of Plasmids: a Limit to Plasmid
387 Transmission. Microbiol Spectr. 2017;5.

388 [16] Kottara A, Hall JPJ, Harrison E, Brockhurst MA. Variable plasmid fitness effects and
389 mobile genetic element dynamics across *Pseudomonas* species. FEMS Microbiol Ecol.
390 2018;94:fix172-fix.

391 [17] Oyedemi BOM, Shinde V, Shinde K, Kakalou D, Stapleton PD, Gibbons S. Novel R-
392 plasmid conjugal transfer inhibitory and antibacterial activities of phenolic compounds
393 from *Mallotus philippensis* (Lam.) Mull. Arg. Journal of Global Antimicrobial Resistance.
394 2016;5:15-21.

395 [18] Kwapong AA, Stapleton P, Gibbons S. A new dimeric imidazole alkaloid plasmid
396 conjugation inhibitor from *Lepidium sativum*. Tetrahedron Lett. 2018;59:1952-4.

397 [19] Rice LB, Bonomo RA. Genetic and biochemical mechanisms of bacterial resistance to
398 antimicrobial agents. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed.
399 USA: Lippincott Williams & Wilkins; 2005. p. 483-4.

400 [20] Hooper DC, Wolfson JS, McHugh GL, Swartz MD, Tung C, Swartz MN. Elimination of
401 plasmid pMG110 from *Escherichia coli* by novobiocin and other inhibitors of DNA
402 gyrase. Antimicrob Agents Chemother. 1984;25:586-90.

403 [21] Molnar A. Antiplasmid effect of promethazine in mixed bacterial cultures. Int J
404 Antimicrob Agents. 2003;22:217-22.

405 [22] Splenger G, Molnar A, Schelz Z, Amaral L, Sharples D, Molnar J. The mechanism of
406 plasmid curing in bacteria. Curr Drug Targets. 2006;7:1389-4501.

407 [23] Molnar J, Mandi Y, Splenger G, Amaral L, Haszon I, Turi S, et al. Synergism between
408 antiplasmid promethazine and antibiotics *in vitro* and *in vivo*. Mol Biol. 2014;04:1-6.

409 [24] Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New
410 colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst.
411 1990;82:1107-12.

412 [25] Romeo L, Iori R, Rollin P, Bramanti P, Mazzon E. Isothiocyanates: An overview of
413 their antimicrobial activity against human infections. Molecules. 2018;23:1-18.

414 [26] Dufour V, Stahl M, Baysse C. The antibacterial properties of isothiocyanates.
415 Microbiology. 2015;161:229-43.

416 [27] Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al.
417 Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of
418 *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl
419 Acad Sci U S A. 2002;99:7610-15.

420 [28] Kim MG, Lee HS. Growth-inhibiting activities of phenethyl isothiocyanate and its
421 derivatives against intestinal bacteria. J Food Sci. 2009;74:M467-M71.

422 [29] Borges A, Abreu AC, Ferreira C, Saavedra MJ, Simoes LC, Simoes M. Antibacterial
423 activity and mode of action of selected glucosinolate hydrolysis products against
424 bacterial pathogens. J Food Sci Technol. 2015;52:4737-48.

425 [30] Nowicki D, Rodzik O, Herman-Antosiewicz A, Szalewska-Pałasz A. Isothiocyanates
426 as effective agents against enterohemorrhagic *Escherichia coli*: insight to the mode of
427 action. Sci Rep. 2016;6:1-12.

428 [31] Lu Z, Dockery CR, Crosby M, Chavarria K, Patterson B, Giedd M. Antibacterial
429 Activities of Wasabi against *Escherichia coli* O157:H7 and *Staphylococcus aureus*. Front
430 Microbiol. 2016;7:1-9.

431 [32] Lin CM, Preston III JF, Wei CI. Antibacterial mechanism of allyl isothiocyanate. J
432 Food Prot. 2000;63:727-34.

433 [33] Sofrata A, Santangelo EM, Azeem M, Borg-Karlson AK, Gustafsson A, Pütsep K.
434 Benzyl isothiocyanate, a major component from the roots of *Salvadora Persica* is highly
435 active against Gram-negative bacteria. PLoS One. 2011;6:1-10.

436 [34] Abreu AC, Borges A, Simoes LC, Saavedra MJ, Simoes M. Antibacterial activity of
437 phenyl isothiocyanate on *Escherichia coli* and *Staphylococcus aureus*. Medicinal
438 Chemistry. 2013;9:756-61.

439 [35] Dufour V, Stahl M, Rosenfeld E, Stintzi A, Baysse C. Insights into the mode of action
440 of benzyl isothiocyanate on *Campylobacter jejuni*. Appl Environ Microbiol.
441 2013;79:6958-68.

442 [36] Smith PA, Romesberg FE. Combating bacteria and drug resistance by inhibiting
443 mechanisms of persistence and adaptation. Nat Chem Biol. 2007;3:549-56.

444